text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며, 제64기 3분기 연결재무정보 및 재무정보는 외부감사인의 감사(검토)를 받지 아니한 것 입니다.\n1) 요약연결재무정보\n국제약품(주) 및 종속기업\xa0 \xa0\n(단위 : 원)\n구 분\n제64기 3분기\n제63기\n제62기\n[유동자산]\n53,547,109,829\xa0\n49,940,201,956\xa0\n61,135,035,867\xa0\n-현금및현금성자산\n7,125,484,763\xa0\n4,013,014,774\xa0\n7,448,034,125\xa0\n-매출채권\n18,886,393,100\xa0\n20,250,681,477\xa0\n20,667,104,826\xa0\n-재고자산\n20,827,334,356\xa0\n21,651,887,423\xa0\n16,595,366,817\xa0\n-기타유동자산\n6,707,897,610\xa0\n4,024,618,282\xa0\n16,424,530,099\xa0\n[비유동자산]\n91,613,056,197\xa0\n95,685,349,934\xa0\n73,458,578,230\xa0\n-유형자산\n80,350,270,076\xa0\n84,882,176,864\xa0\n64,359,978,411\xa0\n-무형자산\n1,390,988,468\xa0\n1,492,236,263\xa0\n1,677,484,748\xa0\n-투자부동산\n3,388,033,096\xa0\n3,488,952,649\xa0\n4,093,469,130\xa0\n-기타비유동자산\n6,483,764,557\xa0\n5,821,984,158\xa0\n3,327,645,941\xa0\n자산총계\n145,160,166,026\xa0\n145,625,551,890\xa0\n134,593,614,097\xa0\n[유동부채]\n54,570,878,543\xa0\n55,357,616,964\xa0\n59,250,771,507\xa0\n[비유동부채]\n18,529,180,434\xa0\n19,769,071,069\xa0\n14,388,889,463\xa0\n부채총계\n73,100,058,977\xa0\n75,126,688,033\xa0\n73,639,660,970\xa0\n[자본금]\n19,276,090,000\xa0\n18,400,520,000\xa0\n18,400,520,000\xa0\n[주식발행초과금]\n2,995,998,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,267,372,639\xa0\n29,335,099,371\xa0\n21,480,876,507\xa0\n[기타자본항목]\n15,770,814,508\xa0\n15,816,353,383\xa0\n16,683,166,546\xa0\n[이익잉여금]\n4,730,124,277\xa0\n3,058,916,238\xa0\n492,983,140\xa0\n지배기업소유주지분\n72,040,399,616\xa0\n70,482,457,184\xa0\n60,929,114,385\xa0\n비지배지분\n19,707,433\xa0\n16,406,673\xa0\n24,838,742\xa0\n자본총계\n72,060,107,049\xa0\n70,498,863,857\xa0\n60,953,953,127\xa0\n부채와자본총계\n145,160,166,026\xa0\n145,625,551,890\xa0\n134,593,614,097\xa0\n매출액\n86,844,386,373\xa0\n130,394,720,787\xa0\n111,121,601,008\xa0\n영업이익\n2,189,097,027\xa0\n6,041,374,040\xa0\n5,570,756,961\xa0\n당기순이익(손실)\n1,788,651,554\xa0\n2,194,568,946\xa0\n(4,761,811,946)\n\xa01.지배기업소유주지분\n1,785,350,794\xa0\n2,203,001,015\xa0\n(4,760,904,168)\n\xa02.비지배지분\n3,300,760\xa0\n(8,432,069)\n(907,778)\n기타포괄손익\n(181,869,487)\n7,350,341,784\xa0\n(2,384,442,638)\n당기총포괄이익(손실)\n1,606,782,067\xa0\n9,544,910,730\xa0\n(7,146,254,584)\n\xa01.지배기업소유주지분\n1,603,481,307\xa0\n9,553,342,799\xa0\n(7,145,346,806)\n\xa02.비지배지분\n3,300,760\xa0\n(8,432,069)\n(907,778)\n주당순이익(손실)\n97\xa0\n126\xa0\n(272)\n연결에 포함된 회사수\n1\xa0\n1\xa0\n1\n<종속기업 재무정보 요약>\n(2021년 3분기)\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,579,002\n369,514\n2,828,598\n61,889\n(2020년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,592,178\n307,625\n3,960,265\n(158,101)\n(2019년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,510,709\n465,726\n2,429,926\n(17,021)\n2) 요약재무정보\n국제약품(주)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n(단위 : 원)\n구 분\n제64기 3분기\n제63기\n제62기\n[유동자산]\n52,974,253,412\xa0\n49,174,515,891\xa0\n60,161,878,936\xa0\n-현금및현금성자산\n6,985,693,540\xa0\n3,658,329,420\xa0\n7,218,053,324\xa0\n-매출채권\n18,513,305,916\xa0\n19,929,859,420\xa0\n20,233,344,301\xa0\n-재고자산\n20,769,683,189\xa0\n21,569,134,807\xa0\n16,296,426,007\xa0\n-기타유동자산\n6,705,570,767\xa0\n4,017,192,244\xa0\n16,414,055,304\xa0\n[비유동자산]\n90,623,012,032\xa0\n94,837,294,329\xa0\n72,940,313,200\xa0\n-유형자산\n79,870,943,373\xa0\n84,465,524,125\xa0\n64,214,202,193\xa0\n-무형자산\n1,326,165,025\xa0\n1,489,062,824\xa0\n1,674,311,309\xa0\n-투자부동산\n3,488,138,674\xa0\n3,592,170,673\xa0\n4,093,469,130\xa0\n-기타비유동자산\n5,937,764,960\xa0\n5,290,536,707\xa0\n2,958,330,568\xa0\n자산총계\n143,597,265,444\xa0\n144,011,810,220\xa0\n133,102,192,136\xa0\n[유동부채]\n54,457,583,833\xa0\n55,168,831,048\xa0\n59,080,611,261\xa0\n[비유동부채]\n18,171,377,020\xa0\n19,415,080,745\xa0\n14,278,918,866\xa0\n부채총계\n72,628,960,853\xa0\n74,583,911,793\xa0\n73,359,530,127\xa0\n[자본금]\n19,276,090,000\xa0\n18,400,520,000\xa0\n18,400,520,000\xa0\n[주식발행초과금]\n2,995,998,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,153,710,898\xa0\n29,236,392,939\xa0\n21,480,876,507\xa0\n[기타자본항목]\n15,944,158,435\xa0\n15,989,697,310\xa0\n16,856,510,473\xa0\n[이익잉여금]\n3,598,347,066\xa0\n1,929,719,986\xa0\n(866,813,163)\n자본총계\n70,968,304,591\xa0\n69,427,898,427\xa0\n59,742,662,009\xa0\n자본과부채총계\n143,597,265,444\xa0\n144,011,810,220\xa0\n133,102,192,136\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n84,029,172,151\xa0\n126,514,615,485\xa0\n108,709,297,057\xa0\n영업이익\n2,120,893,270\xa0\n6,195,143,340\xa0\n5,594,782,551\xa0\n당기순이익(손실)\n1,782,769,835\xa0\n2,433,601,066\xa0\n(4,987,038,125)\n기타포괄손익\n(196,824,796)\n7,251,635,352\xa0\n(2,384,442,638)\n당기총포괄손익\n1,585,945,039\xa0\n9,685,236,418\xa0\n(7,371,480,763)\n주당순이익(손실)\n97\xa0\n139\xa0\n(285)\n']"
